Cargando…

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ziyu, Lin, Yan, Zhang, Jinyan, Zhang, Yumei, Li, Yongqiang, Liu, Zhihui, Li, Qian, Luo, Ming, Liang, Rong, Ye, Jiazhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827249/ https://www.ncbi.nlm.nih.gov/pubmed/31684985 http://dx.doi.org/10.1186/s13046-019-1412-8

Ejemplares similares

Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma
por: Liang, Rong, et al.
Publicado: (2021)

Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic Analysis
por: Zhang, Jinyan, et al.
Publicado: (2018)

Prognosis-Related Molecular Subtypes and Immune Features Associated with Hepatocellular Carcinoma
por: Ye, Jiazhou, et al.
Publicado: (2022)

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review
por: Lin, Yan, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Construction of a Comprehensive Multiomics Map of Hepatocellular Carcinoma and Screening of Possible Driver Genes
por: Liu, Ziyu, et al.
Publicado: (2020)

Homologous Recombination Pathway Alternation Predicts Prognosis of Colorectal Cancer With Chemotherapy
por: Lin, Yan, et al.
Publicado: (2022)

A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma
por: Lin, Yan, et al.
Publicado: (2019)

Research progress on GP73 in malignant tumors
por: Liang, Rong, et al.
Publicado: (2018)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Long non-coding RNA-based risk scoring system predicts prognosis of alcohol-related hepatocellular carcinoma
por: Luo, Yue, et al.
Publicado: (2020)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
por: Dai, Xinlun, et al.
Publicado: (2020)

Expression and gene regulation network of RBM8A in hepatocellular carcinoma based on data mining
por: Lin, Yan, et al.
Publicado: (2019)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
por: Lee, Ahlim, et al.
Publicado: (2022)

Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
por: Shannon, Alexander H., et al.
Publicado: (2023)

Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
por: Sun, Tao, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma
por: Cong, Tianhao, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
por: Zhang, Jin, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis
por: Wang, Xiao‐Hui, et al.
Publicado: (2023)

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
por: Zhang, Rujia, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
por: Li, Si-Qi, et al.
Publicado: (2022)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
por: Luo, Ning, et al.
Publicado: (2023)

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
por: Tsai, Hong-Ming, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
por: Guardascione, Michela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_enk9i65j5qppapkrvdi5b7nlpe